SENSEI BIOTHERAPEUTICS INC. - COMMON STOCK

Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program

04 Aug 2021 07:45:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Appoints Kristian Humer to its Board of Directors

02 Aug 2021 08:01:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal Antibody and Nanobody Programs

28 Jun 2021 16:05:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck

19 May 2021 17:03:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports First Quarter 2021 Results and Provides Business Update

12 May 2021 07:41:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Appoints Maura Gillison, M.D., Ph.D., and Richard Ulevitch, Ph.D., to its Immuno-Oncology Advisory Board

05 May 2021 08:05:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Appoints Jessie M. English, Ph.D. to its Board of Directors

05 Apr 2021 08:00:01 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports Full Year 2020 Results and Provides Business Update

25 Mar 2021 08:00:01 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces Inclusion in Russell 2000 Index

22 Mar 2021 08:00:01 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Present at Oppenheimer 31st Annual Virtual Healthcare Conference

09 Mar 2021 08:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces Closing of Initial Public Offering

10 Feb 2021 16:55:31 By Nasdaq GlobeNewswire